Boothbay Fund Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Boothbay Fund Management’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-73,395	Closed	-$3M	–	2041
2024 Q2	$3M	Buy	+73,395	New	+$3.06M	0.07%	362
2022 Q4	–	Sell	-33,959	Closed	-$960K	–	2543
2022 Q3	$960K	Buy	+33,959	New	+$1.01M	0.02%	900

Other funds holding CERE

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Boothbay Fund Management's CERE Position: Q3 2024 in Review

Boothbay Fund Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 73,395 shares — an estimated $3M sold.

Boothbay Fund Management first reported a position in CERE in Q3 2022 and held it in 2 quarters. The position peaked at $3M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

Boothbay Fund Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Boothbay Fund Management sold 73,395 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $3M.
Boothbay Fund Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2022 and held it in 2 quarters.
Boothbay Fund Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $3M in Q2 2024.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Boothbay Fund Management's 13F filing for Q3 2024, filed 14 Nov 2024.